Subscribe To
KOD / Kodiak Sciences' (KOD) Q3 Earnings Beat, Eye Candidate in Focus
KOD News
By Zacks Investment Research
August 16, 2023
Kodiak (KOD) Q2 Earnings Miss, New Lead Candidate in Focus
Kodiak (KOD) reports weaker-than-expected results in second-quarter 2023. The company also provides an update on the status of its pipeline after disc more_horizontal
By Zacks Investment Research
August 14, 2023
Should You Buy Kodiak Sciences (KOD) Ahead of Earnings?
Kodiak Sciences (KOD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. more_horizontal
By Zacks Investment Research
July 25, 2023
Kodiak (KOD) Down as Late-Stage DME Studies Fail
Kodiak (KOD) stock plunges as it failed to meet the primary endpoint in phase III studies evaluating tarcocimab in diabetic macular edema patients. more_horizontal
By Proactive Investors
July 24, 2023
Kodiak Sciences discontinues development of eye disorder therapeutic; shares plummet
Kodiak Sciences shares fell by more than 45% after the biopharmaceutical company announced that it was discontinuing its tarcocimab program for eye di more_horizontal
By Reuters
July 24, 2023
Kodiak Sciences scraps development of eye disorder drug
Kodiak Sciences Inc decided to discontinue development of its experimental drug to treat a type of eye disorder, sending its shares tumbling 40% in pr more_horizontal
By Zacks Investment Research
June 14, 2023
Why Is Kodiak Sciences Inc. (KOD) Up 62.9% Since Last Earnings Report?
Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? more_horizontal
By Proactive Investors
May 31, 2023
Kodal Minerals says Bouguoni financing date now end June, hits more high-grade lithium
Kodal Minerals and Hainan Mining have agreed to a long stop extension until 30 June 2023 to ratify the financing package for the Bougouni lithium pro more_horizontal
By Zacks Investment Research
May 30, 2023
Kodiak (KOD) Advances With Tarcocimab Amid Stiff Competition
Kodiak (KOD) focuses on completing ongoing studies on tarcocimab for several retinal indications. However, competition in the market and the lack of o more_horizontal